More than 11.5 million people this season have signed up for Obamacare, even as new President Donald Trump has vowed to repeal the law. » Read More
The average deductible of popular types of Obamacare plans jumped by 20 percent in 2017. » Read More
More than 8.8 million people so far have signed up for coverage from the federal Obamacare marketplace HealthCare.gov. » Read More
Mylan has raised the price of EpiPens more than 400 percent in recent years. The medicine inside costs $1.
CNBC's Jim Cramer fired back Thursday on comments from Mylan CEO Heather Bresch about pricing of the auto-injection device EpiPen.
Under pressure, Mylan plans to boost access to its EpiPen Auto-Injector by expanding existing programs for patients who are facing higher costs.
Pharmaceutical company Mylan has reduced the cost of EpiPens for some people — but at the end of the day, its CEO told CNBC she has a business to run.
Should you buy long-term-care insurance? That's the question for workers nearing retirement. The cost of coverage and care is rising.
Price increases on life-saving EpiPens have parents outraged — but the CEO of the company that makes them said no one's more frustrated than her.
Most HealthCare.gov customers could buy health plans for under $100 per month next year even if prices grew by 25 percent.
Mylan announced plans to boost access to its EpiPen Auto-Injector by expanding programs for patients who are facing higher out-of-pocket costs.
Heather Bresch is the daughter of a U.S. senator, incorporated her American company in the Netherlands and got an MBA she wasn't entitled to.
Mylan raised the prices of 24 drug products more than 20 percent. One went up by 542 percent. Another by 444 percent.
Mylan has increased the price of the anti-allergy device EpiPen more than five-fold in recent years.
Two senior lawmakers on the U.S. Senate's Judiciary Committee pushed for information regarding sharp price increases for EpiPens.
Biotech stocks have underperformed the market but that could change as investors bet more deals could be in the making.
Medivation surged more than 19 percent Monday after Pfizer said it would buy the cancer drug company for about $14 billion.
As much as 55 percent of the country will have two or fewer Obamacare insurers to choose from.
Officials have launched an investigation to see if providers may be steering patients into Obamacare plans.
Get the best of CNBC in your inbox